Health policy

Medicines committee recommends two new lung-cancer medicines

The 9–12 November recommendations are not yet EU authorisations. The European Commission still has to decide.

On 13 November 2026, the European Medicines Agency published the outcome of its human medicines committee meeting of 9–12 November. The committee recommended seven new medicines for authorisation. A recommendation is not yet an authorisation. The European Commission decides afterwards.

For adults with non-small cell lung cancer, the most common form of lung cancer, the committee recommended Aumseqa, whose active substance is aumolertinib. For adults with the non-squamous form of this lung cancer, it recommended Zybrivo, whose active substance is sintilimab. Ruxolitinib Krka also received a positive opinion. It is a generic copy of an active substance that is already authorised. It is intended for myelofibrosis and polycythaemia vera in adults, and for graft-versus-host disease in adults and children. Myelofibrosis is a bone-marrow disease in which scar tissue disrupts blood formation. In polycythaemia vera, the bone marrow makes too many red blood cells. Graft-versus-host disease can occur after a transplant, when the donor’s immune cells attack the recipient. This medicine is also still waiting for a Commission decision.

The company applying for catequentinib, for two forms of soft-tissue sarcoma, withdrew its application. That is not a refusal by the committee.

Sources